Modular Medical’s Road to Revenue: Why $MODD’s Pivot Launch Is Becoming a Story Worth Watching -(

A national pharmacy benefit manager contract, new digital learning tools and a focused launch strategy give the insulin-pump developer a more concrete commercial narrative.

Modular Medical, Inc. (NASDAQ: MODD) is assembling something many tend to appreciate more than another promising product presentation: the infrastructure to turn a cleared medical device into a commercial business. A national U.S. pharmacy benefit manager agreement, newly launched patient education tools and a targeted rollout strategy are bringing its Pivot tubeless insulin patch pump closer to the moment when product design must meet prescription demand. The bullish thesis centers on access. Modular Medical is targeting people who could consider insulin-pump therapy but remain on multiple daily injections, while working to make Pivot easier to understand, obtain and incorporate into everyday care. The opportunity is not simply to build another pump. It is to make the transition to pumping feel less like enrolling in an engineering course. That distinction matters. A device can be technically impressive and commercially lonely. Modular Medical’s recent announcements suggest management understands that the road to revenue requires more than a well-designed piece of hardware.

Pivot’s Opening: Make Insulin-Pump Therapy More Approachable

Pivot is a wearable, tubeless system designed to deliver both basal insulin, the background supply, and bolus insulin, the doses associated with meals or corrections, over a three-day wear period. Modular Medical describes the product as a practical pathway from multiple daily injections to pump therapy. During Tribe Public’s September 4, 2026, CEO Presentation and Q&A webinar, “The Road To Revenue: Modular Medical’s Strategy For Launching Pivot,” Chief Executive Officer Jeb Besser explained the company’s focus on what he calls “almost pumpers.” These are prospective users who may be interested in pump therapy but have not made the transition. Rather than requiring satisfied users of existing systems to switch, Modular Medical wants to reach people whose needs management believes are not being adequately addressed. Besser described a two-piece design combining a three-day disposable component with a reusable component intended to last 90 days. He also highlighted a 3 mL insulin reservoir, an on-device bolus button and the ability to remove and reattach the pump during its wear period. Those features underpin management’s pitch that Pivot can offer a simpler experience without abandoning practical flexibility. The investment implication is straightforward: Modular Medical does not need to persuade every insulin-pump user that more features are undesirable. It needs to demonstrate that a meaningful group of prospective users values a more approachable alternative.

Digital Learning Gives the Commercial Strategy Another Layer

On October 15, Modular Medical announced two digital education resources developed with Relevate Health Games to help prospective users become familiar with insulin therapy and Pivot before formal training. One provides an approximately 15-minute virtual walkthrough covering unpacking, preparation, application and basic operation. The second places a Pivot module inside Level One: A Diabetes Game, a free diabetes education game that, according to the announcement, had surpassed 53,000 downloads since its April 2025 launch. The game teaches concepts involving carbohydrate counting, meal planning and mealtime insulin dosing before introducing users to Pivot within that educational setting. For many, the attraction is not that Modular Medical has discovered video games. It is that the company is addressing an obstacle that can sit between a prescription and a successful start: uncertainty about using a device. Management believes these tools could help build patient confidence and support adoption and retention. Healthcare providers may also use the experience to assess interest and readiness for pump therapy. Whether those benefits translate into better conversion or lower support costs remains to be demonstrated, but the commercial logic is coherent: familiarity can make the next step less intimidating. There is an important boundary. These resources are optional educational experiences, not substitutes for professional instruction or individualized dosing guidance. The company explicitly states that the walkthrough is not part of Pivot’s FDA-required training program.

A National PBM Contract Moves the Story Beyond Product Design

Patient interest is useful. A workable reimbursement pathway is considerably more useful. On September 4, Modular Medical announced a contract with a national U.S. pharmacy benefit manager, or PBM, making Pivot available through that organization. The company described the agreement as an important commercialization milestone intended to broaden access to the pump. The PBM was not named. In the webinar held that day, Besser said the agreement was effective immediately, while also explaining that PBM contracting and underlying health-plan formulary placement are separate steps. Many should therefore distinguish access through a national PBM from universal coverage across every plan in its network. Even with that qualification, the agreement is meaningful to the bullish case. Modular Medical is pursuing a pharmacy-benefit model built around recurring prescriptions rather than relying on a large upfront equipment purchase. Besser described patients receiving approximately a month’s supply of disposable cartridges through that prescription process. The appeal is a potentially repeatable commercial relationship. If patients start on Pivot, remain on therapy and refill their prescriptions, the company has the basis for recurring product demand. The operative word is “if.” A reimbursement agreement opens a door. Patient starts and refills reveal how many people actually walk through it.

A Five-Market Launch Favors Focus Over Fireworks

Besser’s September presentation outlined an initially concentrated rollout across five markets:

• Cincinnati and Lexington, treated as one market.
• Atlanta.
• Dallas.
• Houston.
• Tampa.

Management selected these areas using factors including diabetes prevalence, existing pump penetration, willingness to adopt technology, prescriber concentration and payer coverage. Besser said the plan called for five initial sales representatives, with the aim of reaching the right clinicians without immediately building a sprawling national organization. That approach offers a sensible commercial experiment. A focused rollout can help establish which patients respond to the product, which clinicians prescribe it and how much effort is required to turn interest into sustained use. It also gives investors a more realistic framework for early expectations. In September, Besser said he expected October and November sales to be modest as representatives developed prescriber relationships and the first commercial users came onto the system. The October 15 announcement continued to describe Modular Medical as preparing for Pivot’s full commercial launch, so the available materials should not be read as confirmation of a completed broad rollout. For an emerging device company, a measured start need not contradict an ambitious opportunity. Sometimes the most useful launch is the one that produces reliable answers before it produces an expensive national sales meeting.

FDA-Cleared Enhancements Add Flexibility Ahead of Launch

Modular Medical’s commercial preparations have also included product refinements. On September 3, the company announced FDA clearance for Pivot software enhancements covering greater bolus-dose customization, an enhanced user interface and other upgrades. Management said the clearance arrived ahead of its planned fourth-quarter launch. This was clearance of enhancements to the platform, not the original clearance of Pivot itself. In the following day’s webinar, Besser explained that the changes allowed the insulin amount delivered per button press to be customized, rather than remaining fixed at two units. For the investment thesis, the significance is practical rather than theatrical. Modular Medical is trying to preserve Pivot’s simplicity while allowing the device to accommodate different user needs. A straightforward product still has to fit the person wearing it.

Recurring Supplies Could Become the Economic Engine

The most interesting part of Modular Medical’s model may ultimately be less visible than the pump. Besser described a system in which the reusable component is provided when a patient begins therapy, while disposable cartridges are supplied through recurring prescriptions. That structure makes patient retention and refill behavior central to the commercial opportunity. He also argued that reusing expensive components over 90 days could support manufacturing cost advantages at scale. Importantly, he acknowledged that those economics would not necessarily exist with only a small initial user base. Cost leadership is a management objective, not a demonstrated current result. The potential relationship is attractive: more retained users could support more recurring orders, higher manufacturing volumes and improved unit economics. But each link must hold. Enrollment without retention will not establish the model, and volume without adequate net reimbursement will not establish profitability. That is why the most informative future disclosures may be decidedly unglamorous: active users, refill rates, reimbursement experience and manufacturing costs. In medical devices, the spreadsheet eventually requests a seat at the product demonstration.

What Many Should Watch Next

The recent announcements strengthen the commercial setup, but the next stage requires operating evidence. The most useful milestones include:

• Patient starts and continued use. Besser identified a growing user base and patient experiences as important early evidence of commercial viability.
• Reimbursement execution. The PBM agreement must translate into workable access for individual patients and their health plans.
• Prescriber adoption. The focused launch must demonstrate that a small sales organization can generate repeat prescribing activity.
• Education-to-onboarding conversion. The digital tools are designed to improve readiness, but their effect on actual adoption and retention has not yet been established.
• Manufacturing execution. Modular Medical identifies high-volume manufacturing and market acceptance among the risks that could affect its plans.

Those are not reasons to dismiss the opportunity. They are the tests that could make the opportunity more investable.

The Bull Case: A More Complete Commercial Proposition

Modular Medical’s recent progress gives investors several connected developments to evaluate: a pump designed around approachability, a national PBM agreement intended to support access, digital resources intended to reduce uncertainty and a geographically focused launch plan designed to test commercial execution. Together, they form a more substantial narrative than a device awaiting its moment. The company is working on the steps between curiosity and use, then between initial use and recurring demand. The bullish interpretation is that Pivot could find a valuable place among people who have remained outside the pump market. The unresolved question is whether that positioning can produce durable adoption at attractive economics. Nothing in the reviewed materials establishes profitability, a particular stock valuation or a guaranteed investment return. For those following MODD, that leaves a clear proposition: the commercial groundwork is becoming more tangible, and the next meaningful catalyst is evidence that patients and prescribers are responding.

Watch the CEO Presentation and Q&A

Modular Medical CEO Jeb Besser co-hosted Tribe Public’s “The Road To Revenue: Modular Medical’s Strategy For Launching Pivot” on Friday, September 4, 2026. The replay covers the target patient population, initial launch territories, pharmacy-benefit strategy, recurring-supply model and management’s expectations for early commercialization.

Watch the full webinar replay on YouTube.

The Sources

1. Modular Medical. “Modular Medical Launches Digital Learning Tools to Support Adoption of Pivot Insulin Delivery System.” Yahoo Finance / ACCESS Newswire, October 15, 2026.
   https://finance.yahoo.com/healthcare/articles/modular-medical-launches-digital-learning-130000873.html
2. Tribe Public. “The Road To Revenue: Modular Medical’s Strategy For Launching Pivot.” CEO Presentation and Q&A webinar featuring Modular Medical (NASDAQ: MODD) CEO Jeb Besser, September 4, 2026.
   https://www.youtube.com/watch?v=ORcOsdvZOhE
3. Modular Medical. “Modular Medical Announces Contract with National U.S. Pharmacy Benefit Manager, Expanding Access to Pivot Tubeless Patch Pump.” Yahoo Finance / ACCESS Newswire, September 4, 2026.
   https://finance.yahoo.com/healthcare/articles/modular-medical-announces-contract-national-120000363.html
4. Modular Medical. “Modular Medical Announces FDA Clearance of Pivot Tubeless Insulin Patch Pump Enhancements.” ACCESS Newswire, September 3, 2026.
   https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/modular-medical-announces-fda-clearance-of-pivot-tubeless-insulin-pat-1216140
5. Modular Medical. Annual Report on Form 10-K for the fiscal year ended March 31, 2026. U.S. Securities and Exchange Commission. Provides financial statements, business disclosures, commercialization plans and investment risk factors.
   https://www.sec.gov/Archives/edgar/data/1074871/000121390026073223/ea0294762-10k_modular.htm
6. Drug Delivery Business News. “Modular Medical launches Pivot tubeless insulin patch pump.” June 24, 2026. Trade-publication coverage of commercial availability, the phased rollout and the target patient population.
   https://www.drugdeliverybusiness.com/modular-medical-launches-pivot-tubeless-pump/
7. Today’s Medical Developments. “Modular Medical moves forward with Pivot insulin pump commercialization.” August 6, 2026. Trade-publication coverage of the planned five-market rollout.
   https://www.todaysmedicaldevelopments.com/news/modular-medical-moves-forward-pivot-insulin-pump-commercialization/
8. Modular Medical. “Modular Medical Announces Launch of Pivot Insulin Delivery System Across Five Key U.S. Markets Beginning October 2026.” BioSpace / ACCESS Newswire, August 3, 2026. Company announcement outlining its initial commercialization strategy and geographic focus
   https://www.biospace.com/press-releases/modular-medical-announces-launch-of-pivot-insulin-delivery-system-across-five-key-u-s-markets-beginning-october-2026
9. Modular Medical. “Modular Medical to Participate in the Association of Diabetes Care & Education Specialists 2026 Annual Conference.” Yahoo Finance / ACCESS Newswire, August 5, 2026. Company announcement discussing clinician engagement, product demonstrations and launch preparations.
   https://finance.yahoo.com/healthcare/articles/modular-medical-participate-association-diabetes-124500518.html